Breast Cancer Brain Metastases Pre-Clinical Trials

In effort to move novel compounds into the clinical trials arena, Dr. Carey Anders, in collaboration with a team of investigators including Drs. Chuck Perou, Ryan Miller and Matthew Ewend are developing several preclinical breast cancer brain metastases mouse models.

A triple negative breast cancer cell line (MDA-MB-231) will be used and novel therapeutics will be tested to determine if the growth of brain metastases or overall survival of the animals is positively affected by the addition of the agent. Should efficacy be seen, this will provide rationale to move the agent into early phase clinical trials.

In collaboration with Dr. William Zamboni, liposomal drugs will also be tested as this unique formulation has been shown to accumulate in malignant brain tissues in prior studies.

It is our belief that a parallel preclinical/clinical approach will be not only the most efficacious, but will also provide the most timely approach to move promising drugs from the laboratory to the clinic with the overall goal of improving outcomes for our patients diagnosed with breast cancer and brain metastases.

Drs. Carey Anders and Willam Zamboni pictured above.